Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

are expected to be filed by Novartis for both NVA237 and QVA149 in 2011.

Mr Shinichi Tamura, President & CEO of Sosei, commented:

"This represents an important milestone in the clinical development of NVA237 and we look forward also to the anticipated commencement of the Phase III study for QVA149 towards the end of this year."

Dr Chris Blackwell, Chief Executive of Vectura, added: "The Phase II studies demonstrated that NVA237 provides sustained 24-hour bronchodilation in patients with moderate to severe COPD. As it now enters the final stage of clinical development before market, confidence in the product is at a new high as we anticipate confirmation of such benefit in a large target patient population."

Notes for Editors:

About the NVA237 and QVA149 licence agreement with Novartis

Sosei and Vectura Group plc concluded a global development and commercialisation agreement with Novartis in April 2005 for their collaborative product NVA237. Novartis is responsible for developing and commercializing NVA237 both as a monotherapy and in combination with indacaterol, its once daily, long-acting beta-2 agonist, as QVA149.

Under the terms of the agreement, Sosei and Vectura to date have each received $15 million and will each receive up to $172.5 million for achieving pre-agreed clinical, regulatory and commercialisation targets for both the monotherapy and combination product. These potential milestones total up to $375 million. In addition, royalties on product sales will be paid for the monotherapy and the combination product. If additional combination products are developed by Novartis, using NVA237, further milestones and royalties will be payable.

About COPD

COPD is a chronic obstruction of the airways which in the developed world is caused primarily by smoking. Symptoms include chronic bronchitis and/or emphysema whi
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/18/2014)... 21, 2014) -- A group of scientists from ... the Sanders-Brown Center on Aging has found interesting ... neuropsychological function in Parkinson,s disease (PD). , ... the study, which assessed cognitive function in depressed ... dopamine replacement therapy commonly used to treat motor ...
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... Calif. (April 18, 2014) ― A new study in ... weekly patterns in health-related Google searches reveals a recurring ... strategies. , Investigators from San Diego State ... the Monday Campaigns, analyzed "healthy" Google searches (searches that ... "healthy diet") originating in the U.S. from 2005 to ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... BlueShield Give 40 in District Opportunity to Help Community Prevent HIV/AIDS ... ... Education ( SHIRE ), Inc., is reaching out to 40 young men ... prevent the spread of HIV and AIDS and childhood obesity. The ...
... Manhattan Cross Cultural Group is now offering at ... CME cultural competency training course for physicians in New ... by June 30, 2009. New Jersey physicians can sign ... by visiting: http://www.qualityinteractions.org/index.new.html ...
... BETHESDA, Md., May 11 The American College of ... four new directors, following its 2009 annual meeting. The ... for the Foundation and for advancing the policies and ... a term of 5 years, are: Wayne W. Grody, ...
... Karen Ignagni, President and CEO of America,s Health Insurance ... containment framework presented to President Obama:"Health plans are honored ... framework for cost containment, which is essential to make ... and preserve the competitiveness of our country. We strongly ...
... Massachusetts, May 11 ,Optasia Medical Ltd., a ... has received certification for the successful,registration of ... 9001:2008 and ISO,13485:2003. The certification audit was ... 2009. The Intertek auditor examined all elements ...
... northwest region with more hires planned throughout the ... The Pennsylvania Patient Safety Authority has hired ... to help healthcare facilities that report through the ... safety for Pennsylvania citizens. The Patient Safety Liaison ...
Cached Medicine News:Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 3Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 4Health News:Attention New Jersey Physicians Still Needing to Meet Cultural Competency Requirement by June 30 2Health News:New Board Members Join American College of Medical Genetics Foundation (ACMGF): Distinguished Executive, Medical and Philanthropic Leaders Bring Additional Perspectives to the ACMGF Board 2Health News:New Board Members Join American College of Medical Genetics Foundation (ACMGF): Distinguished Executive, Medical and Philanthropic Leaders Bring Additional Perspectives to the ACMGF Board 3Health News:AHIP Statement on Cost Containment Framework 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
... packaged in easy open, single-use foil-laminated ... saturated with precisely the correct amount ... sterilized, ensuring the safest possible product ... is an antiseptic, microbicidal skin cleanser ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
... Swabsticks are packaged in easy open, ... Swabstick is saturated with precisely the ... is terminally sterilized, ensuring the safest ... acts as a prophylactic anti-infective agent ...
... Aplicare's Saturated Swabsticks are packaged ... 4 inch Swabstick is saturated ... of solution. Each package is ... possible product for the patient. ...
Medicine Products: